Photo of Sara Bouberhan,  MD

Sara Bouberhan, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4800

Sara Bouberhan, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Assistant in Medicine, Medicine, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

One of the primary challenges in the management of advanced ovarian cancer is the inability to identify which patients have been cured from front-line treatment. Many patients have already been cured of their disease, but still receive unnecessary maintenance treatment. Many others do not benefit from a given maintenance strategy and receive ineffective treatment which only delivers toxicity. Clinicians do not yet have a tool to guide decision making with more precision. I am working with a group of researchers to develop an ovarian cancer liquid biopsy, which could be applied to this clinical context. A cost-efficient and highly sensitive assay also has the potential to identify mutations predictive of treatment response or resistance, and future research using expanded gene panels could address this possibility.

Publications

Powered by Harvard Catalyst
  • Bouberhan S, Philp L, Hill S, Al-Alem LF, Rueda B. Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers (Basel) 2020. PubMed
  • Bouberhan S, Shea M, Kennedy A, Erlinger A, Stack-Dunnbier H, Buss MK, Moss L, Nolan K, Awtrey C, Dalrymple JL, Garrett L, Liu FW, Hacker MR, Esselen KM. Financial toxicity in gynecologic oncology. Gynecol Oncol 2019; 154:8-12. PubMed
  • Bouberhan S, Shea M, Cannistra SA. Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits? J Clin Oncol 2019; 37:1359-1364. PubMed
  • Bouberhan S, Shea M, Cannistra SA. Maintenance PARP inhibitor therapy: is maintaining quality of life enough? Lancet Oncol. 2018; 19:e504. PubMed
  • Dieffenbach C, Bouberhan S, Raynor E, Shea M, Liu F. Polymyositis as a presentation of advanced carcinoma of Mullerian origin: A case report and discussion. Gynecol Oncol Rep 2019; 25:1-2. PubMed
  • Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, Sanft TB, Abu-Khalaf MM, Chung GG, Stein SM, Goldberg SB, Pusztai L, Hofstatter EW. Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer 2017; 122:1588-97. PubMed
Member Summary Video